Nature reports that limits are being proposed for bets placed on clinical trial outcomes via prediction markets. The move aims to address potential issues arising from financial speculation on medical research results.
T.J.H., with unpaid committee membership to ESMO (Magnitude of Clinical Benefit Scale) and consulting fees from Treehill Partners LLP on pharmaceutical policy, is connected to the issue. The article, published in Nature on May 22, 2026, details the call for restrictions on these types of wagers.
The publication’s correspondence highlights concerns about the integrity of clinical trials and the potential for manipulation if financial incentives are tied to specific outcomes. The article is identified as Nature 657, 566 (2026) with DOI https://doi.org/10.1038/d41586-026-02795-9.
Read the original coverage
💬 Comments
📜 Comment Policy